OBJECTIVE: The aim was to examine the expression and localization of the five somatostatin receptors (termed SSTR1 to 5) in radical prostatectomies (RPs) from patients with prostatic adenocarcinoma (PCa) under complete androgen ablation (CAA) before operation. MATERIAL: The five SSTRs were evaluated in the epithelial, smooth muscle and endothelial cells of normal-looking epithelium (Nep), high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa in 20 RPs with clinically detected PCa from patients under CAA. Twenty RPs with clinically detected PCa from hormonally untreated patients were used as control group. RESULTS: Concerning the secretory cells (i) Membrane staining was seen for SSTR3 and SSTR4; the mean percentages of positive cells, higher in SSTR3 than in SSTR4, decreased sharply in HGPIN and PCa compared with Nep; the mean percentages in the androgen ablated group were 30% to 90% lower than in the untreated; (ii) Cytoplasmic staining was seen for all five SSTRs; the mean percentages of positive cells in Nep, HGPIN and PCa of the untreated group were similar, and in general as high as 80% or more; in the treated group, the Nep values were similar to those in the untreated, whereas the values in HGPIN and PCa were lower for SSTR1, three and five, with a decrease of 30% for SSTR1; (iii) Nuclear staining was seen with SSTR4 and SSTR5, the mean percentages for the former being much lower than for the latter; treatment affected both HGPIN and PCa, whose proportions of stained cells were 30% to 55% lower than in the untreated group. Cytoplasmic staining in the basal cells was seen for all five SSTRs, both in Nep and HGPIN. The values in the treated group were lower than in the other, the difference between the two group being in general comprised between 10% and 40%. Treatment did not affect SSTR staining in the smooth muscle and endothelial cells. CONCLUSIONS: The present study expands our knowledge on the expression and localization of the five SSTRs in the prostate following CAA.
OBJECTIVE: The aim was to examine the expression and localization of the five somatostatin receptors (termed SSTR1 to 5) in radical prostatectomies (RPs) from patients with prostatic adenocarcinoma (PCa) under complete androgen ablation (CAA) before operation. MATERIAL: The five SSTRs were evaluated in the epithelial, smooth muscle and endothelial cells of normal-looking epithelium (Nep), high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa in 20 RPs with clinically detected PCa from patients under CAA. Twenty RPs with clinically detected PCa from hormonally untreated patients were used as control group. RESULTS: Concerning the secretory cells (i) Membrane staining was seen for SSTR3 and SSTR4; the mean percentages of positive cells, higher in SSTR3 than in SSTR4, decreased sharply in HGPIN and PCa compared with Nep; the mean percentages in the androgen ablated group were 30% to 90% lower than in the untreated; (ii) Cytoplasmic staining was seen for all five SSTRs; the mean percentages of positive cells in Nep, HGPIN and PCa of the untreated group were similar, and in general as high as 80% or more; in the treated group, the Nep values were similar to those in the untreated, whereas the values in HGPIN and PCa were lower for SSTR1, three and five, with a decrease of 30% for SSTR1; (iii) Nuclear staining was seen with SSTR4 and SSTR5, the mean percentages for the former being much lower than for the latter; treatment affected both HGPIN and PCa, whose proportions of stained cells were 30% to 55% lower than in the untreated group. Cytoplasmic staining in the basal cells was seen for all five SSTRs, both in Nep and HGPIN. The values in the treated group were lower than in the other, the difference between the two group being in general comprised between 10% and 40%. Treatment did not affect SSTR staining in the smooth muscle and endothelial cells. CONCLUSIONS: The present study expands our knowledge on the expression and localization of the five SSTRs in the prostate following CAA.
Authors: D Morichetti; R Mazzucchelli; A Santinelli; D Stramazzotti; A Lopez-Beltran; M Scarpelli; A V Bono; L Cheng; R Montironi Journal: Int J Immunopathol Pharmacol Date: 2010 Apr-Jun Impact factor: 3.219
Authors: Marco Volante; Maria Pia Brizzi; Antongiulio Faggiano; Stefano La Rosa; Ida Rapa; Anna Ferrero; Gelsomina Mansueto; Luisella Righi; Silvana Garancini; Carlo Capella; Gaetano De Rosa; Luigi Dogliotti; Annamaria Colao; Mauro Papotti Journal: Mod Pathol Date: 2007-09-14 Impact factor: 7.842
Authors: H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts Journal: Gut Date: 2004-08 Impact factor: 23.059
Authors: G Verset; C Verslype; H Reynaert; I Borbath; P Langlet; A Vandebroek; M Peeters; G Houbiers; S Francque; M Arvanitakis; J-L Van Laethem Journal: Br J Cancer Date: 2007-08-07 Impact factor: 7.640
Authors: Zhi Rong Qian; Tingting Li; Monica Ter-Minassian; Juhong Yang; Jennifer A Chan; Lauren K Brais; Yohei Masugi; Arunthathi Thiaglingam; Nichole Brooks; Reiko Nishihara; Mireille Bonnemarie; Atsuhiro Masuda; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Ruoxu Dou; Xihong Lin; David C Christiani; Fabien Schmidlin; Charles S Fuchs; Umar Mahmood; Shuji Ogino; Matthew H Kulke Journal: Pancreas Date: 2016-11 Impact factor: 3.327
Authors: Jan K Hennigs; Julia Müller; Matti Adam; Joshua M Spin; Emilia Riedel; Markus Graefen; Carsten Bokemeyer; Guido Sauter; Hartwig Huland; Thorsten Schlomm; Sarah Minner Journal: PLoS One Date: 2014-07-10 Impact factor: 3.240
Authors: Guisheng Zhou; Jim Sinnett-Smith; Shi-He Liu; Juehua Yu; James Wu; Robbi Sanchez; Stephen J Pandol; Ravinder Abrol; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi Journal: Front Physiol Date: 2014-06-25 Impact factor: 4.566